Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors-Reference-Cited by-同舟云学术

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors

Published:2018-04-27 Issue:5 Volume:69 Page:1861-1872
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Smith David¹^ORCID,Magri Andrea¹²,Bonsall David¹³,Ip Camilla L.C.¹³,Trebes Amy³,Brown Anthony¹,Piazza Palo³,Bowden Rory³^ORCID,Nguyen Dung¹,Ansari M. Azim¹²,Simmonds Peter¹,Barnes Eleanor¹,

Affiliation:

1. Nuffield Department of Medicine and the Oxford NIHR BRCUniversity of Oxford Oxford UK

2. Oxford Martin SchoolUniversity of Oxford Oxford UK

3. Wellcome Trust Centre for Human GeneticsUniversity of Oxford Oxford UK

Funder

Medical Research Council

Wellcome Trust

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29837

Reference45 articles.

1. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

2. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

3. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

4. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C virus subtype distribution and resistance-associated substitutions in high-risk population groups in Guangdong Province, China;Infection, Genetics and Evolution;2024-09

2. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients;JHEP Reports;2024-07

3. ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment;Gut;2024-05-23

4. Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors;Archives of Microbiology;2024-04-15

5. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10